Sanford-Burnham to collaborate with Pfizer on obesity, diabetes drugs; Medidata Solutions closing on $287.5 million offering;

@FierceBiotech: ICYMI: Biotechs crowd list of top growth leaders as Big Pharmas shrink staffs. Feature | Follow @FierceBiotech

@JohnCFierce: If the OS results for necitumumab were more than very, very slim, I'll be surprised. | Follow @JohnCFierce

@RyanMFierce: Why not. Langer's Bind files $80M IPO as new biotech offerings go gangbusters. Story | Follow @RyanMFierce

> The Sanford-Burnham Medical Research Institute in Florida has struck a three-year pact with Pfizer ($PFE) to search for new drugs to treat obesity and diabetes. The institute plans to use tools "including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes." Release

> SciClone Pharmaceuticals says it has received another subpoena from the SEC regarding a probe into foreign corruption. Story

> Medidata Solutions ($MDSO) is scheduled to close on a $287.5 million notes offering Monday, giving the company a surplus of money in the bank to finance potential acquisitions and other business activities. And the major financing should more than double the company's reserves. Report

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices: Medtronic bags telehealth biz for $200M. More | Follow @FierceMedDev

@DamianFierce: GenMark wants to turn the page on June's plunge with a $60M stock sale. Story | Follow @DamianFierce

@MichaelGFierce: Receptor-targeted antifolate drugs yield fewer side effects. More from FierceDrugDelivery | Follow @MichaelGFierce

@MarkHFierce: Modest growth ahead for the U.S. spinal implant market. Article | Follow @MarkHFierce

> Endo ships out urology unit as device sales lurch. News

> Given wins FDA nod for next-gen PillCam device. More

> Baxter wins Chinese OK for $4B Gambro buyout. Story

> Rexam solicits buyers for healthcare packaging arm in potential $1 billion deal. Article

Pharma News

@FiercePharma: Twist for Perrigo's Elan buy, per Leerink Swann: Perrigo must maintain Irish headcount to keep key tax breaks. So cost-cutting ability limited. | Follow @FiercePharma

@CarlyHFierce: Regeneron puts $70M in plant expansion amid growing Eylea demand. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> What do pharma reps need to get face time with doctors? Report

> Lawmakers demand Purdue Pharma's list of suspect OxyContin prescribers. News

> Mylan assures India it won't dismiss domestic market with Agila buy. Item

Pharma Manufacturing News

@EricPFierce: India's Aurobindo Pharma expanding its sterile injectables capacity at newest facility. More from FiercePharma.com | Follow @EricPFierce

> Russia's Pharmstandard to buy Singapore API maker. News

> Compounder recalls drugs that may have caused infections. Item

> Mylan geared up for big expansion in India. More

> Manufacturing issues trip up Novo on new therapy. Article

> India's Aurobindo buys, boosts sterile capacity. Story

Biotech Research News

@EmilyMFierce: U.K. nonprofits offering funding for novel Parkinson's targets. More from FierceBiotechResearch.com | Follow @EmilyMFierce

> NIH to open genomic data of HeLa cells to researchers. Story

> Newly discovered proteins could play role in destroying cancer cells. Article

> Stem cell combo therapy extends survival of mice with brain tumors. More

> University of Maryland, Baltimore partners with 5 biotech companies. Item

And Finally… A new animal study shows that a burst of electricity goes through the brain as rats die, suggesting that the bright light sometimes seen during near-death experiences could be connected to the power surge. Story

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.